Goldman Sachs Downgrades ACADIA Pharmaceuticals to Sell, Lowers Price Target to $12
Goldman Sachs analyst Salveen Richter downgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Neutral to Sell and lowers the price target from $15 to $12.
JP Morgan Downgrades C4 Therapeutics to Neutral, Lowers Price Target to $15
JP Morgan analyst Eric Joseph downgrades C4 Therapeutics (NASDAQ:CCCC) from Overweight to Neutral and lowers the price target from $22 to $15.
B of A Securities Downgrades Maravai LifeSciences to Neutral, Lowers Price Target to $17
B of A Securities analyst Michael Ryskin downgrades Maravai LifeSciences (NASDAQ:MRVI) from Buy to Neutral and lowers the price target from $32 to $17.
UBS Downgrades Clean Harbors to Neutral, Announces $135 Price Target
UBS analyst Jon Windham downgrades Clean Harbors (NYSE:CLH) from Buy to Neutral and announces $135 price target.
Compass Point Downgrades Easterly Government Props to Neutral, Announces $17 Price Target
Compass Point analyst Merrill Ross downgrades Easterly Government Props (NYSE:DEA) from Buy to Neutral and announces $17 price target.
BMO Capital Downgrades Cognizant Tech Solns to Market Perform, Lowers Price Target to $65
BMO Capital analyst Keith Bachman downgrades Cognizant Tech Solns (NASDAQ:CTSH) from Outperform to Market Perform and lowers the price target from $73 to $65.
B. Riley Securities Downgrades Identiv to Neutral, Lowers Price Target to $12
B. Riley Securities analyst Craig Ellis downgrades Identiv (NASDAQ:INVE) from Buy to Neutral and lowers the price target from $19 to $12.
B of A Securities Downgrades Bilibili to Neutral, Lowers Price Target to $11.5
B of A Securities analyst Brad Sills downgrades Bilibili (NASDAQ:BILI) from Buy to Neutral and lowers the price target from $42 to $11.5.
B of A Securities Downgrades AvidXchange Holdings to Underperform, Lowers Price Target to $8
B of A Securities analyst Brad Sills downgrades AvidXchange Holdings (NASDAQ:AVDX) from Neutral to Underperform and lowers the price target from $10 to $8.